Supplementary Table 1. Immunosuppressive drugs used at baseline and management of immunosuppression at the time of Covid-19 diagnosis in kidney transplant recipients with Covid-19 (n = 306).

## Immunosuppressive drugs at baseline

CNI, n (%)	253 (82.7%)
Mycophenolate, n (%)	236 (77.1%)
Azathioprin, n (%)	12 (3.9%)
mTOR inhibitors, n (%)	34 (11.1%)
Steroids, n (%)	230 (75.2%)
Belatacept, n (%)	20 (6.5%)
Immunosuppression management	
CNI withdrawal, n (%)	66 (26.1%)
Antimetabolite withdrawal, n (%)	186 (75.3%)
mTOR inhibitors withdrawal, n (%)	14 (41.2%)
Belatacept withdrawal, n (%)	7 (35.0%)

CNI, calcineurin inhibitors

Supplementary Table 2. Detailed clinical characteristics, management, and outcomes of kidney transplant recipients and non-transplant patients hospitalized for Covid-19

	Non-transplant patients N=795	Transplant recipients N=306	р	N
Baseline characteristics	,-		_	_
Median age [IQR], years	69.0 [57.0-79.0]	62.0 [52.0-69.0]	< 0.001	1101
Age > 60 years - n (%)	555 (69.8%)	176 (57.5%)	< 0.001	1101
Men - n (%)	466 (58.6%)	207 (67.6%)	0.007	1101
Median BMI [IQR] - kg/m <sup>2</sup>	28.0 [24.0-32.0]	26.0 [23.0-30.0]	< 0.001	1016
$BMI > 25 \text{ kg/m}^2 - \text{n (\%)}$	527 (73.2%)	184 (62.2%)	0.001	1016
Hypertension - n (%)	420 (52.8%)	260 (90.9%)	< 0.001	1081
RAS blockers - n (%)	272 (34.2%)	133 (47.7%)	< 0.001	1074
Cardiovascular disease - n (%)	256 (32.2%)	128 (41.8%)	0.003	1101
Respiratory disease - n (%)	136 (17.1%)	40 (13.1%)	0.122	1101
Diabetes - n (%)	198 (24.9%)	122 (39.9%)	< 0.001	1101
Cancer - n (%)	81 (10.2%)	37 (12.1%)	0.420	1101
Smoking - n (%)	31 (3.9%)	31 (12.4%)	< 0.001	1044
Clinical presentation				
Anosmia - n (%)	74 (13.3%)	35 (13.0%)	0.993	825
Cough - n (%)	498 (62.6%)	178 (65.7%)	0.410	1066
Dyspnea - n (%)	501 (63.0%)	140 (45.8%)	< 0.001	1101
Fever - n (%)	590 (74.2%)	219 (80.5%)	0.044	1067
Headache - n (%)	119 (15.0%)	45 (18.1%)	0.271	1043
Diarrhea - n (%)	202 (25.4%)	105 (36.6%)	< 0.001	1082
Time from diagnosis to admission [IQR] - days	7.0 [3.0-10.0]	5.0 [3.0-8.0]	0.006	1004
Laboratory data				
Median CRP [IQR] - mg/L	85 [38-148]	62 [27-118]	0.001	965
Median lymphocyte count [IQR] - C	0.89 [0.65-1.24]	0.70 [0.40-0.96]	< 0.001	976
Median platelet count [IQR] - G/L	195 [151-254]	176 [145-234]	0.017	988
Thrombocytopenia <150 G/L - n (%	186 (24%)	63 (29%)	0.153	988
Median creatinine [IQR] - $\mu$ mol/L	75 [59-100]	176 [132-254]	< 0.001	1026
Treatments				
Azithromycin - n (%)	329 (41.4%)	75 (24.5%)	< 0.001	1101
Other antibiotics - n (%)	599 (75.3%)	203 (66.3%)	0.003	1101
Antifungal drugs - n (%)	17 (2.1%)	14 (4.6%)	0.028	1101
Remdesivir - n (%)	5 (0.6%)	2 (0.7%)	1.000	1101

	Non-transplant patients N=795	Transplant recipients N=306	р	N
Lopinavir/ritonavir - n (%)	173 (21.8%)	16 (5.2%)	< 0.001	1101
Oseltamivir - n (%)	8 (1.0%)	7 (2.3%)	0.142	1101
Hydroxychloroquine - n (%)	151 (19.0%)	69 (22.5%)	0.216	1101
Tocilizumab - n (%)	8 (1.0%)	17 (5.6%)	< 0.001	1101
Outcome				
Viral coinfection - n (%)	7 (0.9%)	9 (2.9%)	0.020	1101
Fungal coinfection - n (%)	8 (1.0%)	12 (3.9%)	0.003	1101
Oxygen therapy - n (%)	480 (73.1%)	189 (73.8%)	0.879	913
Mechanical ventilation - n (%)	269 (33.8%)	86 (28.1%)	0.080	1101
Vasopressor support - n (%)	184 (23.1%)	41 (13.4%)	< 0.001	1101
Acute kidney injury - n (%)	89 (11.2%)	141 (46.1%)	< 0.001	1101
Renal replacement therapy - n (%)	64 (8.1%)	39 (12.7%)	0.023	1101

Abbreviations: IQR, interquartile range; BMI, body mass index; ICU, intensive care unit; RAS, renin-angiotensin system; CRP, C-reactive protein.

Data are summarized using medians (IQRs) or counts (percentages), as appropriate.

## Figure legend

**Supplementary Figure 1.** Thirty-day cumulative incidence of the composite endpoint (ICU admission or death) and Covid-19-related mortality only in non-transplant patients (solid line) and kidney transplant recipients (dashed line). Data are presented for unmatched cohorts.

- A) Composite endpoint (non-transplant patients: 43.8%, kidney transplant recipients: 41.2%).
- B) Covid-19-related mortality only (non-transplant patients: 17.0 %, kidney transplant recipients: 16.6%).